Online first: DREAMM-2 study: phase 2 trial of #belantamab mafodotin for relapsed or refractory #multiplemyeloma
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study #mmsm
$GSK Anti-BCMA ADC pivotal data out 31% ORR 3% CR 27% Gr3/4 keratopathy Very hard to see how this risk/benefit profile can be competitive in the super crowded BCMA space. No wonder this data couldn't get into #ASH19 LBA.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study - The Lancet Oncology #mmsm
Belantamab for MM: why such a drop off in ORR? Was 60% in DREAMM1, now 31-34%.. Need to figure out how to solve the keratopathy!
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study - The Lancet Oncology ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ #mmsm
#𝟯 𝗗𝗥𝗘𝗔𝗠𝗠-𝟮 Belantamab mafodotin (GSK2857916) active in relapsed refractory myeloma. Response rate 30-35% & PFD 3-5 months is lower than expected. Corneal (eye) toxicity is a concern. We need more data. But promising
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study - The Lancet Oncology
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study [Dec 16, 2019] et al. #mmsm
Belantamab mafodotin single agent for relapse/refractory myeloma: ORR 31-34% in a phase 2 randomized trial (DREAMM-2) et al #mmsm
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study: 31-34% overall response rate. Most common grade 3–4 adverse events incl keratopathy in 21-27% of pts #mmsm